Ronald Tam – CFO, XTALPI
Ronald Tam, CFO of XTALPI, delves into the company’s evolution from its MIT origins to becoming a global leader in AI-driven drug discovery. Tam discusses the strategic decision to expand…
Address: 22F, N.138 Pudong Avenue
Shanghai 200120 P.R. China ,China
Tel: +86 21 5888 2200
Web: http://www.boehringer-ingelheim.com.cn/
Entering the Chinese market in 1994, Boehringer Ingelheim investment ushered in vigorous development. Boehringer Ingelheim has excellent products in the prescription drugs, consumer self-care medicines and animal health field in the Chinese market and are widely recognized by consumers.
Since 2002, the company has been based in Shanghai. The Zhangjiang Hi-Tech Park factory was built to demonstrate the Boehringer Ingelheim’s determination to further establish itself in China. The Zhangjiang plant has introduced the world’s most advanced pharmaceutical equipment, design and management standards to the country and is comparable to Boehringer Ingelheim plants in any part of the world. The factory operates in strict accordance to international GMP standards. Boehringer Ingelheim’s investment in China amounts $ 29,000,000. The Company has offices in Shanghai, in Beijing, Guangzhou, Shenyang, Chengdu, Nanjing, Hangzhou and has also set up branches in other places, employing a total of more than 2,000 people.
Boehringer Ingelheim’s main business in China includes prescription drugs, consumer self-care medicines and animal health. The business scope encompasses all of the country’s major cities and regions. The company will continue to pursue new drug and disease treatment programs and Boehringer Ingelheim products have gained an excellent reputation in the market, benefitting millions of patients.
Looking ahead, Boehringer Ingelheim Shanghai looks forward to even greater success in the Chinese market, including in the field of human medicine, the company wants to be the key leader in the respiratory, cardiovascular, central nervous system, diabetes and cancer fields. as well as animal health.
With a solid foundation built up over more than a century, Boehringer Ingelheim strives to make greater contributions to Chinese medical and health undertakings.
respiratory, cardiovascular, central nervous system, diabetes, oncology
Ronald Tam, CFO of XTALPI, delves into the company’s evolution from its MIT origins to becoming a global leader in AI-driven drug discovery. Tam discusses the strategic decision to expand…
The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director…
A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive…
Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations.…
Olivier Dessajan, CEO of Colisée China and Co-President of the French Healthcare Alliance, discusses Colisée’s long-term investment strategies in China, the challenges of navigating the local regulatory environment, and the…
Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships…
Adept at identifying promising biotechs, Qiming Venture Partners-backed companies saw no less than eight IPOs last year. Managing Partner Nisa Leung provides an update on the firm’s activities in light…
Coming to ALK China from an extensive and varied career, Xian Ji has helped build a new strategy for the allergy specialist’s local affiliate, which has led to quintupled business…
A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese…
Dr James Xue, founder, chairman and CEO of CANbridge Pharmaceuticals shares the career journey that led him to China’s first rare disease-focused company and the role CANbridge is playing in…
Drawing on a wealth of Big Pharma experience, Jenny Zheng now leads China operations for Illumina, a global leader in genomics, specialising in DNA sequencing technology that drives innovation in…
Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a…
See our Cookie Privacy Policy Here
